Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Invested Capital (2016 - 2025)

Cytosorbents' Invested Capital history spans 15 years, with the latest figure at $5.9 million for Q4 2025.

  • Quarterly results put Invested Capital at $5.9 million for Q4 2025, down 46.85% from a year ago — trailing twelve months through Dec 2025 was $5.9 million (down 46.85% YoY), and the annual figure for FY2025 was $5.9 million, down 46.85%.
  • Invested Capital for Q4 2025 was $5.9 million at Cytosorbents, down from $24.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $77.3 million in Q1 2021 to a low of $5.9 million in Q4 2025.
  • The 5-year median for Invested Capital is $29.0 million (2023), against an average of $35.0 million.
  • The sharpest move saw Invested Capital skyrocketed 112.24% in 2021, then crashed 61.06% in 2024.
  • Year by year, Invested Capital stood at $62.6 million in 2021, then crashed by 43.47% to $35.4 million in 2022, then dropped by 19.37% to $28.5 million in 2023, then crashed by 61.06% to $11.1 million in 2024, then plummeted by 46.85% to $5.9 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $5.9 million, $24.0 million, and $11.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.